Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody therapy in aggressive lymphomas.

Thomas M Habermann1

  • 1Thomas Habermann, MD, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905-0002, USA. habermann.thomas@mayo.edu

Hematology. American Society of Hematology. Education Program
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026
Same author

MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.

Cancer research communications·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Monoclonal antibody therapy, particularly targeting CD20, has significantly improved outcomes for aggressive lymphomas like diffuse large B-cell lymphoma. New antibody approaches continue to advance treatment for these potentially curable cancers.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Aggressive lymphomas are a group of potentially curable cancers.
  • The natural history of these lymphomas has been significantly impacted by advancements in therapy.

Purpose of the Study:

  • To review the contributions of antibody therapies to the treatment of aggressive lymphomas.
  • To highlight how targeted antibody treatments have changed patient outcomes.

Main Methods:

  • Review of current literature on antibody-based therapies for lymphomas.
  • Discussion of specific antibody targets such as CD20 and CD22.
  • Analysis of antibody incorporation into standard chemotherapy regimens (e.g., CHOP, EPOCH, HyperCVAD).

Main Results:

Related Experiment Videos

  • Targeted monoclonal antibody therapy against CD20 has improved outcomes for diffuse large B-cell lymphoma across all age groups.
  • Anti-CD20 radioimmunoconjugates are being investigated for relapsed disease and stem cell transplant settings.
  • Single-agent anti-CD20 therapy shows activity in post-transplantation lymphoproliferative disorders.

Conclusions:

  • Targeted antibody therapy has fundamentally altered the natural history of several aggressive non-Hodgkin lymphomas.
  • Ongoing research explores new antibody targets (e.g., CD22, CD40) and T-cell antibodies for T-cell lymphoproliferative disorders.
  • Antibody therapies are now integral to the management of aggressive lymphomas, offering improved prognoses.